Skip to main content
Fig. 2 | Translational Neurodegeneration

Fig. 2

From: Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer’s disease-related pathologies in a senescence-accelerated mouse model

Fig. 2

Pharmacological action of the δ-secretase inhibitor 11. a The enzymatic activity of AEP was measured by a 45-min fluorescent substrate cleavage assay. b The concentration-response of δ-secretase inhibitor 11 on AEP activity. Data were obtained at 45 min after the substrate cleavage reaction, n = 5 independent experiments. c The enzymatic activity of AEP in brains of SAMP8 and SAMR1 mice was measured by a 45-min fluorescent substrate cleavage assay. d AEP activity was obtained at 45 min after the substrate cleavage reaction and compared between groups. *P < 0.05, n = 6 mice per group, one-way ANOVA followed by a Tukey’s post-hoc test. e, f Measurement of Aβ1–40 and Aβ1–42 in the brains of SAMP8 mice treated with vehicle or δ-secretase inhibitor 11. *P < 0.05, unpaired Student’s t-test; n = 6 mice per group

Back to article page